BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin AL, Donoghue MTA, Wardlaw SL, Yang TJ, Bodei L, Tabar V, Geer EB. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. J Clin Endocrinol Metab 2020;105:dgaa649. [PMID: 32930787 DOI: 10.1210/clinem/dgaa649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Xi Z, Jones PS, Mikamoto M, Jiang X, Faje AT, Nie C, Labelle KE, Zhou Y, Miller KK, Soberman RJ, Zhang X. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. Front Endocrinol (Lausanne) 2021;12:726448. [PMID: 34745002 DOI: 10.3389/fendo.2021.726448] [Reference Citation Analysis]
2 Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, Hernando J, Martínez-Saez E, Biagetti B, Capdevila J. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report. Front Endocrinol (Lausanne) 2021;12:731631. [PMID: 34858324 DOI: 10.3389/fendo.2021.731631] [Reference Citation Analysis]
3 Cui J, Shen J, Ru X, Tian Z, Duan Z, Chen G, Li M, Zhong WL. A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors. Journal of Oncology 2022;2022:1-5. [DOI: 10.1155/2022/4618664] [Reference Citation Analysis]
4 Auriemma RS, Gahete MD, Gatto F. Editorial: Resistance to Medical Therapy in Pituitary Tumors. Front Endocrinol 2022;13:861230. [DOI: 10.3389/fendo.2022.861230] [Reference Citation Analysis]
5 Lin AL, Tabar V, Young RJ, Cohen M, Cuaron J, Yang TJ, Rosenblum M, Rudneva VA, Geer EB, Bodei L. Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma. J Endocr Soc 2021;5:bvab133. [PMID: 34466766 DOI: 10.1210/jendso/bvab133] [Reference Citation Analysis]
6 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]
7 Goichot B, Taquet MC, Baltzinger P, Baloglu S, Gravaud M, Malouf GG, Noël G, Imperiale A. Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. Clin Endocrinol (Oxf) 2021. [PMID: 34845727 DOI: 10.1111/cen.14645] [Reference Citation Analysis]
8 Yamamoto M, Nakao T, Ogawa W, Fukuoka H. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. Front Endocrinol (Lausanne) 2021;12:650791. [PMID: 34220707 DOI: 10.3389/fendo.2021.650791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]